JW Pharmaceutical Presents Preclinical Results and Global Development Strategy for DDC-02, a Novel Therapeutic Candidate for Rare Neurodevelopmental Disorders

JW Pharmaceutical highlighted the therapeutic potential of DDC-02 in multiple neurodevelopmental disorder models at WODC USA ...

Applied Biologics Launches Preclinical Development Program Focused on Osteoarthritis and Other Degenerative Diseases

Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet ...

SureNano Science (CSE: SURE) (OTCQB: SURNF) Accelerates Development Strategy for Lead Candidate

Austin, Texas, June 12th, 2026, FinanceWireDisseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: ...
MSN on MSN

Purple Biotech presents new IM1240 preclinical data showing anti-tumor activity and broad therapeutic window (PPBT)

New data presented at EACR 2026 highlighted anti-tumor activity, improved safety characteristics, and pharmacokinetic ...
Pharmabiz

JW Pharma announces preclinical results and global development strategy for DDC-02 at World Orphan Drug Congress USA 2026

JW Pharma announces preclinical results and global development strategy for DDC-02 at World Orphan Drug Congress USA 2026: Seoul, South Korea Saturday, June 13, 2026, 16:00 Hrs [I ...
GEN

Integrated Strategies to Accelerate Pre-Clinical Development of Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma. In this GEN webinar, ...
Nasdaq

NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025

TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company ...

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater ...
Contract Pharma

Lonza Enhances Biologics Preclinical Development Offering

DNA‑to‑IND offering leveraging GS Ori‑Go designed to deliver tox material in approximately two months, and IND readiness in ...
The Scientist

Understanding the Drug Development Process

This Brush Up is sponsored by MilliporeSigma. Learn more about therapeutic synthesis pathways. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...